R&D Boosting clinical trial productivity to prove Eroom wrong According to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least in part, bearing that out.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
